Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipoplatin plus gemcitabine as first-line treatment in inoperable locally advanced or metastatic pancreatic cancer
2006-005485-40Phase 2Withdrawn
- Sponsor
- Regulon, Inc.
- Start
- Oct 2009
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of lipoplatin in pancreatic adenocarcinoma (PDAC), sponsored by Regulon, Inc. Primary endpoint: Phase II primary endpoint. Planned start Oct 2009; status: withdrawn.
02
Drugs
lipoplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2006-005485-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005485-40.